L. Rolfe

发表

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

M. Erlander, H. Wakelee, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).

H. Wakelee, L. Sequist, B. Solomon, 2014 .

Recent Pharmacological Advances: Focus on Small-cell Lung Cancer

A. Dalgleish, C. Galustian, V. Sung, 2010 .

Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment.

V. Heinemann, C. Bassi, H. Wasan, 2013 .

Blockade of PDGF receptor beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and increased tumor vascularised volume

G. Parker, G. Jayson, A. Jackson, 2005 .

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

G J M Parker, G. Parker, G. Jayson, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease

L. Sequist, L. Rolfe, A. Allen, 2015 .

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Anne Floquet, Andrew R Allen, James X. Sun, 2017, The Lancet. Oncology.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

A. Biankin, S. Domchek, R. McWilliams, 2018, JCO precision oncology.

Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis.

R. Yelensky, A. Tinker, A. Oza, 2015 .

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Cesar M. Castro, James X. Sun, A. Tinker, 2017, Gynecologic oncology.

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

A. Oza, Y. Drew, G. Shapiro, 2017, Clinical Cancer Research.

Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2

K. Davies, G. Jayson, J. Soranson, 2007, Clinical Cancer Research.

Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)

C. Paweletz, P. Angenendt, H. Wakelee, 2016, Clinical Cancer Research.

A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.

M. Lowery, D. Ryan, M. Saif, 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

V. Heinemann, A. Dicker, C. Bassi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rucaparib in patients with relapsed, primary platinum-sensitive high-grade ovarian carcinoma with germline or somatic BRCA mutations: Integrated summary of efficacy and safety from the phase II study ARIEL2

A. Tinker, A. Oza, E. Swisher, 2017 .

Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).

H. Wakelee, L. Sequist, S. Ou, 2016 .

Phase I and DCE-MRI evaluation of CDP791, a di-Fab PEG conjugate that inhibits VEGFR2

G. Jayson, J. Soranson, A. Jackson, 2007 .

Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer.

L. Sequist, L. Rolfe, A. Allen, 2015, The New England journal of medicine.

A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO‐101 in Patients With Advanced Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2013, Journal of clinical pharmacology.

Abstract P6-11-03: A phase 2 open-label study of lucitanib in patients (pts) with FGF aberrant metastatic breast cancer (MBC)

L. Pusztai, W. Gradishar, R. Nanda, 2017 .

Abstract B136: Plasma EGFR mutation detection using a combined exosomal RNA and circulating tumor DNA approach in patients with acquired resistance to first-generation EGFR-TKIs

Tina Koestler, H. Wakelee, L. Sequist, 2015 .

P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC)

H. Wakelee, E. Smit, S. Novello, 2017 .

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma

M. Erlander, H. Wakelee, L. Sequist, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acute Renal Failure After Cardiopulmonary Bypass: A Possible Association With Drugs of the Fibrate Group

B. Madden, R. Millner, J. Parker, 2000, Journal of cardiovascular pharmacology and therapeutics.

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

A. Oza, Y. Drew, G. Shapiro, 2017, Clinical Cancer Research.